<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131715" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ustekinumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Colquhoun</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Northwick Park Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kemp</surname>
            <given-names>Alysia K.</given-names>
          </name>
          <aff>Karmanos Cancer Institute Wayne State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Colquhoun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alysia Kemp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131715.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ustekinumab is a medication used to manage and treat a variety of inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease. It is in the monoclonal antibody class of medications. This activity reviews the indications, action, and contraindications for ustekinumab as a valuable agent in treating inflammatory diseases. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management of psoriasis, psoriatic arthritis, and inflammatory bowel disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of ustekinumab.</p></list-item><list-item><p>Describe the indications for the use of ustekinumab.</p></list-item><list-item><p>Review the potential adverse event that can accompany ustekinumab use.</p></list-item><list-item><p>Outline strategies utilized by healthcare teams to improve care coordination and communication when ustekinumab is being administered.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131715&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131715">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131715.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn disease, or moderate to severe ulcerative colitis (inflammatory bowel disease).&#x000a0;Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). The drug is FDA approved for use in moderate to severe plaque psoriasis (Ps), particularly in those patients&#x000a0;who are candidates for phototherapy or systemic therapy, aged 6 or older. Patients with active psoriatic arthritis (PsA) may use ustekinumab as monotherapy or in combination with methotrexate.</p>
        <p>More recently, ustekinumab has been approved for moderate to severely active Crohn disease (CD)&#x000a0;and ulcerative colitis (UC). While ustekinumab has not received FDA approval for many other inflammatory mediated diseases, it has been used off label for the treatment of hidradenitis suppurativa, Takayasu arteritis, giant cell arteritis,&#x000a0;Behcet disease, myelodysplastic syndrome, pyoderma grangrenosum, pityriasis rubra pilaris, synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, Lichen planus, atopic dermatitis&#x000a0;as well as systemic lupus erythematosus.<xref ref-type="bibr" rid="article-131715.r1">[1]</xref><xref ref-type="bibr" rid="article-131715.r2">[2]</xref><xref ref-type="bibr" rid="article-131715.r3">[3]</xref><xref ref-type="bibr" rid="article-131715.r4">[4]</xref><xref ref-type="bibr" rid="article-131715.r5">[5]</xref><xref ref-type="bibr" rid="article-131715.r6">[6]</xref><xref ref-type="bibr" rid="article-131715.r7">[7]</xref><xref ref-type="bibr" rid="article-131715.r8">[8]</xref><xref ref-type="bibr" rid="article-131715.r9">[9]</xref><xref ref-type="bibr" rid="article-131715.r10">[10]</xref><xref ref-type="bibr" rid="article-131715.r11">[11]</xref><xref ref-type="bibr" rid="article-131715.r12">[12]</xref></p>
      </sec>
      <sec id="article-131715.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>IL-12 and IL-23 are cytokines that modulate lymphocyte function and have been implicated in the pathogenesis of inflammatory diseases such as psoriasis, psoriatic arthritis, multiple sclerosis, and inflammatory bowel disease.<xref ref-type="bibr" rid="article-131715.r13">[13]</xref>&#x000a0;IL-12 is a cytokine produced by antigen-presenting cells such as dendritic cells and macrophages involved in the development of Th1 cells, which secrete interferon-gamma.<xref ref-type="bibr" rid="article-131715.r14">[14]</xref>&#x000a0;</p>
        <p>IL-23 is a pro-inflammatory cytokine predominantly produced by dendritic cells, monocytes, and macrophages, which causes the differentiation and activation of Th17. Both cytokines share a p40 subunit.<xref ref-type="bibr" rid="article-131715.r15">[15]</xref>&#x000a0;As a human monoclonal IgG1 antibody,&#x000a0;ustekinumab blocks the p40 subunit, and this antagonistic action inhibits the interaction of these cytokines with&#x000a0;the IL-12R&#x003b2;1 receptor. The IL-12R&#x003b2;1 receptor is found on the surface of NK cells and T cells. In doing so, ustekinumab can inhibit IL-12 and IL-23 signaling, activation, and cytokine production resulting in downregulation of the immune system, which reduces inflammation and alters the body's immune response.<xref ref-type="bibr" rid="article-131715.r16">[16]</xref>&#x000a0;Serum concentrations are proportional to dose.<xref ref-type="bibr" rid="article-131715.r17">[17]</xref></p>
      </sec>
      <sec id="article-131715.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ustekinumab is available for injection in pre-filled syringes and vials. The drug is administered by either subcutaneous injection or intravenous infusion. The dosage and administration recommendations depend on the particular indication for treatment and the patient's weight.&#x000a0;</p>
        <p>
<bold>Dosage Forms and Strengths</bold>
</p>
        <p>Subcutaneous injection:</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection: 45 mg/0.5 mL or 90mg/mL solution in a pre-filled syringe</p>
          </list-item>
          <list-item>
            <p>Injection: 45 mg/0.5 mL solution in a single-dose vial</p>
          </list-item>
        </list>
        <p>Intravenous infusion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection: 130 mg/26 mL (5 mg/mL) in a single-dose vial</p>
          </list-item>
        </list>
        <p>
<bold>Dosage and Administration</bold>
</p>
        <p>Psoriasis adult S/C recommended dosage:</p>
        <list list-type="bullet">
          <list-item>
            <p>Less than or equal to 100 kg: 45 mg administered subcutaneously initially, followed by another injection four weeks later and then every 12 weeks</p>
          </list-item>
          <list-item>
            <p>Greater than 100 kg: 90 mg administered subcutaneously initially, followed by another injection four weeks later and then every 12 weeks.<xref ref-type="bibr" rid="article-131715.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>Psoriatic arthritis adult S/C recommended dosage:</p>
        <list list-type="bullet">
          <list-item>
            <p>Less than or equal to 100 kg: 45 mg administered subcutaneously initially, followed by another injection four weeks later and then every 12 weeks</p>
          </list-item>
          <list-item>
            <p>Greater than 100 kg with co-existent moderate-severe plaque psoriasis: 90mg administered subcutaneously initially, followed by another injection four weeks later and then every 12 weeks.<xref ref-type="bibr" rid="article-131715.r19">[19]</xref><xref ref-type="bibr" rid="article-131715.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Psoriasis pediatric patients recommended subcutaneous dosage:</p>
        <p>Doses are administered initially, four weeks later, and then every 12 weeks.<xref ref-type="bibr" rid="article-131715.r21">[21]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Weight &#x0003c; 60 kg: 0.75 mg/kg subcutaneously</p>
          </list-item>
          <list-item>
            <p>Weight 60&#x000a0;to 100 kg: 45 mg subcutaneously</p>
          </list-item>
          <list-item>
            <p>Weight &#x0003e; 100 kg: 90 mg subcutaneously</p>
          </list-item>
        </list>
        <p>Crohn disease and ulcerative colitis treatment are based on an initial intravenous weight-based&#x000a0;infusion followed by a subcutaneous maintenance schedule.<xref ref-type="bibr" rid="article-131715.r22">[22]</xref><xref ref-type="bibr" rid="article-131715.r23">[23]</xref></p>
        <p>Initial infusion dosage:</p>
        <list list-type="bullet">
          <list-item>
            <p>Weight &#x0003c; 55 kg: 260 mg (2 vials)</p>
          </list-item>
          <list-item>
            <p>Weight 55&#x000a0;to 85 kg : 390 mg (3 vials)</p>
          </list-item>
          <list-item>
            <p>Weight &#x0003e; 85 kg: 520 mg (4 vials)</p>
          </list-item>
        </list>
        <p>Crohn disease and ulcerative colitis recommended adult&#x000a0;S/C maintenance dosage:</p>
        <list list-type="bullet">
          <list-item>
            <p>90 mg&#x000a0;subcutaneously eight weeks after initial intravenous administration and every eight weeks after that.</p>
          </list-item>
        </list>
        <p>Renal dosing (including both hemodialysis and peritoneal dialysis) and hepatic dosing are undefined.</p>
      </sec>
      <sec id="article-131715.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Mild side effects (as outlined below) have been reported among ustekinumab&#x000a0;users. Major side effects&#x000a0;such as serious infections and major adverse cardiovascular events&#x000a0;are rare. The&#x000a0;adverse event&#x000a0;profile is similar between psoriasis and psoriatic arthritis patients. However, abdominal pain, fever, and diarrhea have been reported for maintenance doses of ustekinumab for Chrohn and ulcerative colitis patients.<xref ref-type="bibr" rid="article-131715.r24">[24]</xref><xref ref-type="bibr" rid="article-131715.r25">[25]</xref><xref ref-type="bibr" rid="article-131715.r26">[26]</xref><xref ref-type="bibr" rid="article-131715.r27">[27]</xref></p>
        <p>The following adverse effects have been reported:</p>
        <p>
<bold>Serious Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe infections or exacerbation/reactivation of existing infection&#x000a0;(bacterial, mycobacterial, fungal, viral)</p>
          </list-item>
          <list-item>
            <p>Malignancy (e.g., non-melanoma skin cancer)</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity reactions/anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Reversible posterior leukoencephalopathy syndrome</p>
          </list-item>
          <list-item>
            <p>Cryptogenic organizing pneumonia</p>
          </list-item>
          <list-item>
            <p>Interstitial or eosinophilic pneumonia</p>
          </list-item>
        </list>
        <p>
<bold>Common Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngitis</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Vomiting after induction in inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Injection site erythema</p>
          </list-item>
          <list-item>
            <p>Bronchitis/upper respiratory tract infection</p>
          </list-item>
          <list-item>
            <p>Sinusitis</p>
          </list-item>
          <list-item>
            <p>Abdominal pain, fever, influenza, and diarrhea while used for maintenance therapy in inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Back pain</p>
          </list-item>
        </list>
        <p>
<bold>Other Reported Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pruritus</p>
          </list-item>
          <list-item>
            <p>Pustular and erythrodermic psoriasis</p>
          </list-item>
          <list-item>
            <p>Exfoliative dermatitis&#x000a0;</p>
          </list-item>
        </list>
        <p>Ustekinumab has been generally well tolerated by patients in clinical trials, with most adverse events being mild in severity.<xref ref-type="bibr" rid="article-131715.r28">[28]</xref></p>
      </sec>
      <sec id="article-131715.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to ustekinumab or any of the excipients&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Active infection&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Active tuberculosis</p>
          </list-item>
        </list>
        <p>
<bold>Caution Recommended</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Latex hypersensitivity (with the pre-filled syringe dose form)</p>
          </list-item>
          <list-item>
            <p>Patients aged over 60</p>
          </list-item>
          <list-item>
            <p>Chronic or recurrent infections</p>
          </list-item>
          <list-item>
            <p>Latent tuberculosis or those with TB risk</p>
          </list-item>
          <list-item>
            <p>Malignancy of a history of malignancy</p>
          </list-item>
          <list-item>
            <p>prolonged immunosuppressant therapy</p>
          </list-item>
          <list-item>
            <p>Allergen immunotherapy</p>
          </list-item>
          <list-item>
            <p>Photochemotherapy (PUVA)</p>
          </list-item>
        </list>
        <p>As with all biological medications, appropriate screening for severe infection must be carried out before beginning a drug such as ustekinumab; this includes screening for infections such as tuberculosis, HIV, hepatitis B, and hepatitis C and treatment if identified.&#x000a0;Providers must exercise caution in recommending treatment for elderly patients, patients with a history of malignancy, or a predisposition to infection.<xref ref-type="bibr" rid="article-131715.r29">[29]</xref></p>
        <p>Ustekinumab can be used during pregnancy. Based on limited human data, there is no expected risk of fetal harm, and teratogenicity has not been demonstrated in animal studies at up to 100 times the maximum recommended human dose (MRHD). The drug may also be used during breastfeeding; no human data is currently available, but there is no expectation of infant harm based on the drug's properties. No human data exist regarding ustekinumab's effect on milk production.<xref ref-type="bibr" rid="article-131715.r30">[30]</xref><xref ref-type="bibr" rid="article-131715.r31">[31]</xref></p>
      </sec>
      <sec id="article-131715.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Baseline Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Routine blood tests: complete blood count, urea and electrolytes, liver function tests, and inflammatory markers (CRP/ESR)</p>
          </list-item>
          <list-item>
            <p>Varicella antibody status should be clarified, and vaccination considered in appropriate patients</p>
          </list-item>
          <list-item>
            <p>Screening for tuberculosis should be done with a chest X-ray and interferon-gamma release assay<xref ref-type="bibr" rid="article-131715.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatitis B, C, and HIV</p>
          </list-item>
          <list-item>
            <p>Pregnancy&#x000a0;testing should be performed in female patients where&#x000a0;pregnancy is a possibility</p>
          </list-item>
        </list>
        <p>
<bold>Ongoing Monitoring</bold>
<xref ref-type="bibr" rid="article-131715.r32">[32]</xref>
<xref ref-type="bibr" rid="article-131715.r33">[33]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The patients must be monitored clinically for the development of severe infections, including TB, jaundice, malignancy, non-infectious pneumonia, posterior reversible encephalopathy syndrome, or serious skin conditions such as exfoliative dermatitis or erythrodermic psoriasis. Patients additionally should be encouraged to report any concerning symptoms.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Routine blood tests, including&#x000a0;full blood count, urea, electrolytes, liver function tests, and inflammatory markers (CRP/ESR), should be checked approximately every 4&#x000a0;to 6 months.<xref ref-type="bibr" rid="article-131715.r32">[32]</xref><xref ref-type="bibr" rid="article-131715.r33">[33]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Clinical monitoring for efficacy should be carried out using disease-specific measuring systems for psoriasis, psoriatic arthritis, and inflammatory bowel disease.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Re-testing for hepatitis and HIV can be considered if clinically indicated.</p>
          </list-item>
          <list-item>
            <p>There are experimental data to suggest that monitoring serum drug levels may be beneficial during ustekinumab treatment, but this is not the current standard of care.<xref ref-type="bibr" rid="article-131715.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131715.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ustekinumab is a well-tolerated drug with a favorable safety profile. No dose-related or cumulative toxicity was observed during follow-up studies.<xref ref-type="bibr" rid="article-131715.r35">[35]</xref>&#x000a0;Given that ustekinumab is a biologic medication that inhibits the normal functioning of the immune system, there is theoretically an increased risk of infection, and clinical evidence of infection should be evaluated at each follow-up visit. Limited pregnancy and breastfeeding data are available, and more studies are needed to confirm safe use during pregnancy.<xref ref-type="bibr" rid="article-131715.r36">[36]</xref>&#x000a0;</p>
        <p>There have been reports of the rapid development of cutaneous squamous cell carcinoma in those patients treated with ustekinumab. These patients often had risk factors for developing this type of cancer, such as being older (greater than 60) and having undergone phototherapy or other immunosuppressant treatment. Patients should be monitored closely for the development of non-melanoma skin cancers.<xref ref-type="bibr" rid="article-131715.r37">[37]</xref>&#x000a0;As with all biological drugs, live vaccines should not be administered while on ustekinumab treatment.<xref ref-type="bibr" rid="article-131715.r38">[38]</xref></p>
      </sec>
      <sec id="article-131715.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of inflammatory diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel disease is complex and associated with a high-cost burden. The rational and cost-effective use of biological medications, such as ustekinumab, is a key component in managing&#x000a0;these diseases. To achieve the desired outcome, an interprofessional healthcare team approach is necessary. Internal medicine clinicians (including mid-level practitioners such as nurse practitioners and physician assistants) may work with specialists, including rheumatologists, gastroenterologists, or dermatologists, to confirm the diagnosis and decide on a treatment course. Nurses facilitate the preparation and administration of medications, as well as monitoring patients after use; they should immediately report any concerns to the ordering/prescribing clinician. Pharmacists can ensure no relevant drug-drug interactions exist, evaluate the relevance of contraindications to treatment, verify dosing is correct (especially inasmuch as ustekinumab utilizes weight-based dosing regimens), and ensure the appropriateness of prescriptions. All clinical personnel need to participate in patient counseling, educate the patient regarding potential adverse events, signs of therapeutic failure, and provide access to resources and points of contact should they need to reach out to the interprofessional team. Social workers identify barriers to compliance and provide resources to patients. Each member of the&#x000a0;interprofessional team's contributions can&#x000a0;provide expertise from their discipline to help drive a positive outcome for patients with potentially fewer adverse events and improve the effectiveness of the broader healthcare system. [Level 5]</p>
      </sec>
      <sec id="article-131715.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131715&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131715">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131715/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131715">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131715.s11">
        <title>References</title>
        <ref id="article-131715.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Tsokos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Touma</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chevrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Triebel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Oct</month>
            <day>13</day>
            <volume>392</volume>
            <issue>10155</issue>
            <fpage>1330</fpage>
            <page-range>1330-1339</page-range>
            <pub-id pub-id-type="pmid">30249507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Mart&#x000ed;nez</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ruiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moneva-L&#x000e9;niz</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Mateu-Puchades</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>e14054</fpage>
            <pub-id pub-id-type="pmid">32700796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirouse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desbois</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Comarmond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000e8;ne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Domont</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferfar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saadoun</surname>
                <given-names>D</given-names>
              </name>
              <collab>French Beh&#x000e7;et's Network</collab>
            </person-group>
            <article-title>Long-Term Outcome of Ustekinumab Therapy for Beh&#x000e7;et's Disease.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1727</fpage>
            <page-range>1727-1732</page-range>
            <pub-id pub-id-type="pmid">31008548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez Gonz&#x000e1;lez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000e1;zaro S&#x000e1;ez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moreno Moraleda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez Mart&#x000ed;nez</surname>
                <given-names>&#x000c1;</given-names>
              </name>
            </person-group>
            <article-title>Pyoderma gangrenosum solved by ustekinumab therapy.</article-title>
            <source>Gastroenterol Hepatol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>299</fpage>
            <page-range>299-300</page-range>
            <pub-id pub-id-type="pmid">33069432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yachoui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreidy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siorek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment with ustekinumab for corticosteroid- and immunosuppressant-resistant Takayasu's arteritis.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2018</year>
            <month>May</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-247</page-range>
            <pub-id pub-id-type="pmid">28276951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matza</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Unizony</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Reply.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>1059</fpage>
            <page-range>1059-1060</page-range>
            <pub-id pub-id-type="pmid">33161642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Molloy</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>1056</fpage>
            <page-range>1056-1057</page-range>
            <pub-id pub-id-type="pmid">32961039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kono</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kashida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Minaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takenaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagiwara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Enoki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.</article-title>
            <source>Intern Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>58</volume>
            <issue>14</issue>
            <fpage>2029</fpage>
            <page-range>2029-2033</page-range>
            <pub-id pub-id-type="pmid">30996178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volc-Platzer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>CARD14-mutations in pityriasis rubra pilaris and therapeutic response to ustekinumab - a hypothesis.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1312</fpage>
            <page-range>1312-1315</page-range>
            <pub-id pub-id-type="pmid">32881385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solimani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pollmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Savai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hlenbein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pickert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eubel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>M&#x000f6;bs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eming</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hertl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1808</fpage>
            <pub-id pub-id-type="pmid">31417572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of ustekinumab in the treatment of atopic dermatitis.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>539</fpage>
            <page-range>539-541</page-range>
            <pub-id pub-id-type="pmid">29164954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daoussis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Konstantopoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kraniotis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sakkas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liossis</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Biologics in SAPHO syndrome: A systematic review.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>618</fpage>
            <page-range>618-625</page-range>
            <pub-id pub-id-type="pmid">29773231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schurich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ciurtin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-254</page-range>
            <pub-id pub-id-type="pmid">28541488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guzzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Che Mat</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The IL-12 family of cytokines in infection, inflammation and autoimmune disorders.</article-title>
            <source>Inflamm Allergy Drug Targets</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-52</page-range>
            <pub-id pub-id-type="pmid">19275692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duvallet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Semerano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Assier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Falgarone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boissier</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Interleukin-23: a key cytokine in inflammatory diseases.</article-title>
            <source>Ann Med</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>503</fpage>
            <page-range>503-11</page-range>
            <pub-id pub-id-type="pmid">21585245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Peritt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scallon</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Heavner</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Shealy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Giles-Komar</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mascelli</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.</article-title>
            <source>MAbs</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>535</fpage>
            <page-range>535-45</page-range>
            <pub-id pub-id-type="pmid">22123062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adedokun</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gasink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jacobstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szapary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johanns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Feagan</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.</article-title>
            <source>Gastroenterology</source>
            <year>2018</year>
            <month>May</month>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>1660</fpage>
            <page-range>1660-1671</page-range>
            <pub-id pub-id-type="pmid">29409871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Szapary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yeilding</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guzzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dooley</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>K</given-names>
              </name>
              <collab>PHOENIX 2 study investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>May</month>
            <day>17</day>
            <volume>371</volume>
            <issue>9625</issue>
            <fpage>1675</fpage>
            <page-range>1675-84</page-range>
            <pub-id pub-id-type="pmid">18486740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Apaolaza</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kafka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of ustekinumab in biologic-na&#x000ef;ve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.</article-title>
            <source>RMD Open</source>
            <year>2019</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e000990</fpage>
            <pub-id pub-id-type="pmid">31565242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helliwell</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kafka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karyekar</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Effects of ustekinumab on spondylitis-associated endpoints in TNFi-na&#x000ef;ve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.</article-title>
            <source>RMD Open</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">32209721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landells</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eichenfield</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hoeger</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Philipp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szapary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Randazzo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>594</fpage>
            <page-range>594-603</page-range>
            <pub-id pub-id-type="pmid">26259989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sands</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Panaccione</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Johanns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adedokun</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peyrin-Biroulet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van Assche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Targan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hisamatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Szapary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marano</surname>
                <given-names>C</given-names>
              </name>
              <collab>UNIFI Study Group</collab>
            </person-group>
            <article-title>Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Sep</month>
            <day>26</day>
            <volume>381</volume>
            <issue>13</issue>
            <fpage>1201</fpage>
            <page-range>1201-1214</page-range>
            <pub-id pub-id-type="pmid">31553833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feagan</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Gasink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jacobstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Johanns</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Adedokun</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Targan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Villiers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tulassay</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Seidler</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Salzberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Desreumaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Dieleman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
              <collab>UNITI&#x02013;IM-UNITI Study Group</collab>
            </person-group>
            <article-title>Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>17</day>
            <volume>375</volume>
            <issue>20</issue>
            <fpage>1946</fpage>
            <page-range>1946-1960</page-range>
            <pub-id pub-id-type="pmid">27959607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Ferrer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The safety of ustekinumab for the treatment of psoriatic arthritis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>733</fpage>
            <page-range>733-742</page-range>
            <pub-id pub-id-type="pmid">28441904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Feagan</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Volger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tikhonov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gasink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.</article-title>
            <source>Inflamm Bowel Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>994</fpage>
            <page-range>994-1007</page-range>
            <pub-id pub-id-type="pmid">32964215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-179</page-range>
            <pub-id pub-id-type="pmid">28300862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poizeau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Nautout</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Droitcourt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drici</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sbidian</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guillot</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachelez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ait-Oufella</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Happe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dupuy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Nov</month>
            <day>01</day>
            <volume>156</volume>
            <issue>11</issue>
            <fpage>1208</fpage>
            <page-range>1208-1215</page-range>
            <pub-id pub-id-type="pmid">32902568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Ustekinumab.</article-title>
            <source>BioDrugs</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-61</page-range>
            <pub-id pub-id-type="pmid">19344192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Jabbar-Lopez</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Bale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hadoke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>MacMahon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nelson-Piercy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Parslew</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peleva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pottinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Samarasekera</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Stoddart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strudwicke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Exton</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Mohd Mustapa</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.</article-title>
            <source>Br J Dermatol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>177</volume>
            <issue>3</issue>
            <fpage>628</fpage>
            <page-range>628-636</page-range>
            <pub-id pub-id-type="pmid">28513835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flanagan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prentice</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Begun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sparrow</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosella</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiburg</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>700</fpage>
            <page-range>700-704</page-range>
            <pub-id pub-id-type="pmid">34907546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorodensky</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bernatsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Afif</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Filion</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Vinet</surname>
                <given-names>&#x000c9;</given-names>
              </name>
            </person-group>
            <article-title>Ustekinumab Safety in Pregnancy: A Comprehensive Review.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>930</fpage>
            <page-range>930-935</page-range>
            <pub-id pub-id-type="pmid">34748293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holroyd</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Seth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bukhari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malaviya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Litwic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Topliffe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ledingham</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>372</fpage>
            <pub-id pub-id-type="pmid">30239912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Raine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hendy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Limdi</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hayee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lomer</surname>
                <given-names>MCE</given-names>
              </name>
              <name>
                <surname>Parkes</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Selinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gittens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunlop</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Faiz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garrick</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Parkes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>H</given-names>
              </name>
              <collab>IBD guidelines eDelphi consensus group</collab>
              <name>
                <surname>Gaya</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brookes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hawthorne</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.</article-title>
            <source>Gut</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>Suppl 3</issue>
            <fpage>s1</fpage>
            <page-range>s1-s106</page-range>
            <pub-id pub-id-type="pmid">31562236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsakok</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dand</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Loeff</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Bloem</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baudry</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Duckworth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pushpa-Rajah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Standing</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alsharqi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Becher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wahie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CEM</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rispens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stocken</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <collab>British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium</collab>
            </person-group>
            <article-title>Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>155</volume>
            <issue>11</issue>
            <fpage>1235</fpage>
            <page-range>1235-1243</page-range>
            <pub-id pub-id-type="pmid">31532460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szapary</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Wasfi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghislain</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>K</given-names>
              </name>
              <collab>PHOENIX 1 Investigators</collab>
              <collab>PHOENIX 2 Investigators</collab>
              <collab>ACCEPT Investigators</collab>
            </person-group>
            <article-title>Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.</article-title>
            <source>Br J Dermatol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>168</volume>
            <issue>4</issue>
            <fpage>844</fpage>
            <page-range>844-54</page-range>
            <pub-id pub-id-type="pmid">23301632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gisbert</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chaparro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>11</issue>
            <fpage>1085</fpage>
            <page-range>1085-1100</page-range>
            <pub-id pub-id-type="pmid">32562207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Czarnecki</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.</article-title>
            <source>Australas J Dermatol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">22309334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131715.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>ZZN</given-names>
              </name>
              <name>
                <surname>Bale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>MacMahon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mahil</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nelson-Piercy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Parslew</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uthman</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Manounah</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ezejimofor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Exton</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Mohd Mustapa</surname>
                <given-names>MF</given-names>
              </name>
              <collab>British Association of Dermatologists&#x02019; Clinical Standards Unit</collab>
            </person-group>
            <article-title>British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.</article-title>
            <source>Br J Dermatol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>183</volume>
            <issue>4</issue>
            <fpage>628</fpage>
            <page-range>628-637</page-range>
            <pub-id pub-id-type="pmid">32189327</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
